Department of Anesthesiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Department of Anesthesiology, Mayo Clinic, Chicago, IL, USA.
Neuromodulation. 2021 Dec;24(8):1351-1356. doi: 10.1111/ner.13317. Epub 2020 Nov 22.
Implantable pulse generator (IPG) site pain following neuromodulation procedures is a recognized complication. The site of the IPG placement varies depending on the neuromodulation type and physician preference. The incidence of IPG site pain as a function of the site of IPG implantation has not been studied systematically.
We performed a multicenter cross-sectional survey of the incidence, severity, and quality of IPG site pain, location of the IPG, the pain management needs, functional impairment, and cosmetic appearance related to the IPG placement. Contingency table analysis was conducted for categorical variables, and logistic regression analysis and linear regression model was used.
The survey response rate was 60.5% (n = 510). Overall, 31.0% of patients reported pain at the IPG site in the last 72 hours with 31.4% reporting moderate to severe pain and 7.6% reporting severe pain. Older age was inversely associated with IPG-related pain (OR = 0.97, 95% CI = 0.96-0.99, p = 0.001). IPG implantation site did not have a statistically significant interaction with IPG site pain (p > 0.05). The most important factor for IPG site-associated pain was having a spinal cord stimulator implanted as compared to a deep brain stimulator, or sacral nerve stimulator. Most subjects reported no functional impairment related to IPG site pain (91%), found the IPG site pain as expected (80%), and found IPG site cosmetic appearance as expected (96%).
The incidence of IPG site pain is an important complication of invasive neuromodulation. The anatomic location of the IPG placement does not appear to affect the incidence or severity of IPG site pain. However, the presence of a pre-implant chronic pain disorder does appear to affect the frequency and severity of IPG site pain.
神经调节术后植入式脉冲发生器(IPG)部位疼痛是一种公认的并发症。IPG 的放置部位取决于神经调节的类型和医生的偏好。IPG 植入部位与 IPG 部位疼痛发生率的关系尚未系统研究过。
我们对 IPG 部位疼痛的发生率、严重程度和质量、IPG 的位置、与 IPG 放置相关的疼痛管理需求、功能障碍和美容外观进行了多中心横断面调查。对分类变量进行了列联表分析,并进行了逻辑回归分析和线性回归模型。
调查的回复率为 60.5%(n=510)。总体而言,31.0%的患者在过去 72 小时内报告 IPG 部位疼痛,31.4%报告中度至重度疼痛,7.6%报告重度疼痛。年龄越大,与 IPG 相关的疼痛呈负相关(OR=0.97,95%CI=0.96-0.99,p=0.001)。IPG 植入部位与 IPG 部位疼痛之间没有统计学上的显著交互作用(p>0.05)。与植入脊髓刺激器相比,植入深部脑刺激器或骶神经刺激器是 IPG 部位相关疼痛的最重要因素。大多数患者报告 IPG 部位疼痛没有导致功能障碍(91%),认为 IPG 部位疼痛是预期的(80%),认为 IPG 部位的美容外观是预期的(96%)。
IPG 部位疼痛的发生率是侵入性神经调节的一个重要并发症。IPG 放置的解剖位置似乎并不影响 IPG 部位疼痛的发生率或严重程度。然而,植入前慢性疼痛障碍的存在似乎会影响 IPG 部位疼痛的频率和严重程度。